相关临床试验
201
36 进行中
药物批准
76
批准总数
监管机构
5
监管机构数
成立时间
1935
进行中（未招募）
14
7.0%
已完成
132
65.7%
尚未招募
22
10.9%
招募中
25
12.4%
暂停
4
2.0%
Unknown
4
2.0%
- Indian pharmaceutical companies including Hetero Labs, Cipla, Annora Pharma, and Natco Pharma have successfully won bids to supply generic drugs to Chinese hospitals through the country's volume-based procurement process. - Hetero Drugs and Cipla secured contracts to supply one billion tablets of Dapagliflozin, a diabetes medication that dominates China's small molecule drug market with sales exceeding 8 billion RMB ($1.14 billion). - The breakthrough represents a significant opportunity for Indian firms to penetrate China's pharmaceutical market, traditionally dominated by multinational companies, despite pricing pressures and competition from cost-advantaged local manufacturers.
- Two major therapeutic efficacy studies in Mozambique and Liberia demonstrate that artemisinin-based combination therapies maintain high cure rates above 90% WHO thresholds despite emerging resistance concerns in East Africa. - In Mozambique, four antimalarial combinations showed PCR-corrected efficacy rates of 97.6-100%, with artemether-lumefantrine maintaining consistent performance over multiple years of surveillance. - Liberian study results confirm both artemether-lumefantrine and artesunate-amodiaquine remain highly effective with 94-100% cure rates, supporting continued use as first-line treatments.
